{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:12:33Z","timestamp":1768893153035,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Spanish Network for AIDS Research"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en Sida","award":["RD16\/0025\/0003"],"award-info":[{"award-number":["RD16\/0025\/0003"]}]},{"name":"ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Decay of HIV in seminal plasma (SP) and rectal fluid (RF) has not yet been described for the antiretroviral combination of dolutegravir (DTG) + lamivudine (3TC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this randomized multicenter pilot trial, males who were antiretroviral naive were randomized (2:1) to DTG + 3TC or bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF). HIV-1 RNA was measured in blood plasma (BP), SP, and RF at baseline; days 3, 7, 14, and 28; and weeks 12 and 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 25 individuals enrolled, 24 completed the study (DTG + 3TC, n = 16; BIC\/FTC\/TAF, n = 8). No significant differences were observed between groups for median decline in HIV-1 RNA from baseline at each time point or median time to achieve HIV-1 RNA &amp;lt;20 copies\/mL in BP and SP and &amp;lt;20 copies\/swab in RF. HIV-1 RNA decay patterns were compared in individuals receiving DTG + 3TC. Despite significantly higher percentages for changes from baseline in BP, median (IQR) times to HIV-1 RNA suppression were shorter in SP (7 days; 0\u20138.75) and RF (10.5 days; 3\u201317.5) than in BP (28 days; 14\u201384; P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Comparable HIV-1 RNA decay in BP, SP, and RF was observed between DTG + 3TC and BIC\/FTC\/TAF. As shown with triple-drug integrase inhibitor\u2013based regimens, rapid HIV-1 RNA suppression in SP and RF is achieved with DTG + 3TC, despite decay patterns differing from those of BP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>EudraCT 2019-004109-28.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad304","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T12:01:34Z","timestamp":1690891294000},"page":"919-925","source":"Crossref","is-referenced-by-count":2,"title":["Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir\/Emtricitabine\/Tenofovir Alafenamide"],"prefix":"10.1093","volume":"228","author":[{"given":"Sof\u00eda","family":"Sc\u00e9vola","sequence":"first","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Niub\u00f3","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5770","authenticated-orcid":false,"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"HIV Unit, Santa Creu i Sant Pau Hospital , Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Verdejo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sant Camil Hospital, Sant Pere de Ribes, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Research Institute, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-9334","authenticated-orcid":false,"given":"Vicens","family":"Diaz-Brito","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de D\u00e9u, Sant Boi de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Pe\u00f1afiel","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet del Llobregat , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Morenilla","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Garcia","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Soriano","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-1952","authenticated-orcid":false,"given":"Arkaitz","family":"Imaz","sequence":"additional","affiliation":[{"name":"HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2023100319161974900_jiad304-B1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"Engl J Med"},{"key":"2023100319161974900_jiad304-B2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2023100319161974900_jiad304-B3","doi-asserted-by":"crossref","first-page":"e1991","DOI":"10.1093\/cid\/ciaa1416","article-title":"Dynamics of the decay of human immunodeficiency virus (HIV) RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naive adults living with HIV-1 treated with bictegravir\/emtricitabine\/tenofovir alafenamide (Spanish HIV\/AIDS Research Network, PreEC\/RIS 58)","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023100319161974900_jiad304-B4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cid\/cix358","article-title":"Viral kinetics in semen with different antiretroviral families in treatment-naive human immunodeficiency virus-infected patients: a randomized trial","volume":"65","author":"Gutierrez-Valencia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023100319161974900_jiad304-B5","doi-asserted-by":"crossref","first-page":"77ra29","DOI":"10.1126\/scitranslmed.3001888","article-title":"Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission","volume":"3","author":"Baeten","year":"2011","journal-title":"Sci Transl Med"},{"key":"2023100319161974900_jiad304-B6"},{"key":"2023100319161974900_jiad304-B7","author":"European AIDS Clinical Society Guidelines"},{"key":"2023100319161974900_jiad304-B8"},{"key":"2023100319161974900_jiad304-B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023100319161974900_jiad304-B10","doi-asserted-by":"crossref","first-page":"e00375-19","DOI":"10.1128\/JVI.00375-19","article-title":"Advances toward curing HIV-1 infection in tissue reservoirs","volume":"94","author":"Henderson","year":"2020","journal-title":"J Virol"},{"key":"2023100319161974900_jiad304-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023100319161974900_jiad304-B12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"2023100319161974900_jiad304-B13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2023100319161974900_jiad304-B14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/COH.0b013e32835fc68a","article-title":"Overcoming pharmacologic sanctuaries","volume":"8","author":"Cory","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2023100319161974900_jiad304-B15","first-page":"162","article-title":"Genital tract reservoirs","volume":"1","author":"Galvin","year":"2006","journal-title":"Curr Opin HIV AIDS"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad304\/51261627\/jiad304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/7\/919\/51840670\/jiad304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/7\/919\/51840670\/jiad304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:23:14Z","timestamp":1696360994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/7\/919\/7234537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad304","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,8,1]]}}}